Diagnosis of Hepatocellular Carcinoma: Role of Tumor Markers and Liver Biopsy

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 297-306

  Gonzalez, Stevan A ^a   Keeffe, Emmet B ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fetoprotein; Cirrhosis; Des carboxyprothrombin; Glypican 3; Hepatocellular carcinoma; Immunohistochemistry; Proteomics

Indexed keywords

ALPHA FETOPROTEIN; ALPHA LEVO FUCOSIDASE; AMINOTRANSFERASE; DECARBOXYPROTHROMBIN; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; MENADIONE EPOXIDE; SQUAMOUS CELL CARCINOMA ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA1;

AMINOTRANSFERASE BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR SEEDING;

BIOPSY; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; HUMANS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959318059     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.012     Document Type: Review

References (57)

1. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
2. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
3. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
5. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010, 000:1-35. Available at:, Accessed November 20, 2010. http://publish.aasld.org/practiceguidelines/Documents/Bookmarked%2520Practice%2520Guidelines/HCCUpdate2010.pdf.
6. Burrel M., Llovet J.M., Ayuso C., et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003, 38:1034-1042.
7. Forner A., Vilana R., Ayuso C., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
8. Sangiovanni A., Manini M.A., Iavarone M., et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010, 59:638-644.
9. Leoni S., Piscaglia F., Golfieri R., et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010, 105:599-609.
10. Mizejewski G.J. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 2001, 226:377-408.
11. Terentiev A.A., Moldogazieva N.T. Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc) 2006, 71:120-132.
12. Adachi Y., Tsuchihashi J., Shiraishi N., et al. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology 2003, 65:95-101.
13. Shen W.F., Zhong W., Xu F., et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 2009, 15:5976-5982.
14. Di Bisceglie A.M., Sterling R.K., Chung R.T., et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005, 43:434-441.
15. Farinati F., Marino D., De Giorgio M., et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol 2006, 101:524-532.
16. Gebo K.A., Chander G., Jenckes M.W., et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002, 36:S84-S92.
17. Gupta S., Bent S., Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003, 139:46-50.
18. Daniele B., Bencivenga A., Megna A.S., et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004, 127:S108-S112.
19. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
20. Trevisani F., D'Intino P.E., Morselli-Labate A.M., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
21. Nguyen M.H., Garcia R.T., Simpson P.W., et al. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002, 36:410-417.
22. Rapaccini G.L., Pompili M., Caturelli E., et al. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 2004, 24:124-130.
23. Vibert E., Azoulay D., Hoti E., et al. Progression of alpha-fetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010, 10:129-137.
24. Sato Y., Nakata K., Kato Y., et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993, 328:1802-1806.
25. Shiraki K., Takase K., Tameda Y., et al. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995, 22:802-807.
26. Wang S.S., Lu R.H., Lee F.Y., et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996, 25:166-171.
27. Sterling R.K., Jeffers L., Gordon F., et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007, 102:2196-2205.
28. Inagaki Y., Tang W., Makuuchi M., et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin. Liver Int 2011, 31(1):22-35.
29. Ishii M., Gama H., Chida N., et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000, 95:1036-1040.
30. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
31. Lok A.S., Sterling R.K., Everhart J.E., et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138:493-502.
32. Nakamura S., Nouso K., Sakaguchi K., et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006, 101:2038-2043.
33. Sung Y.K., Hwang S.Y., Park M.K., et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003, 94:259-262.
34. Zhu Z.W., Friess H., Wang L., et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48:558-564.
35. Capurro M.I., Xiang Y.Y., Lobe C., et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005, 65:6245-6254.
36. Hippo Y., Watanabe K., Watanabe A., et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004, 64:2418-2423.
37. Nakatsura T., Yoshitake Y., Senju S., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
38. Capurro M., Wanless I.R., Sherman M., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
39. Liu H., Li P., Zhai Y., et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010, 16:4410-4415.
40. Poon T.C., Yip T.T., Chan A.T., et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003, 49:752-760.
41. Paradis V., Degos F., Dargere D., et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005, 41:40-47.
42. Schwegler E.E., Cazares L., Steel L.F., et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005, 41:634-642.
43. Zinkin N.T., Grall F., Bhaskar K., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008, 14:470-477.
44. Roskams T., Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010, 30:17-25.
45. Bolondi L., Gaiani S., Celli N., et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005, 42:27-34.
46. Durand F., Regimbeau J.M., Belghiti J., et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001, 35:254-258.
47. Caturelli E., Solmi L., Anti M., et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004, 53:1356-1362.
48. Durand F., Belghiti J., Paradis V. Liver transplantation for hepatocellular carcinoma: role of biopsy. Liver Transpl 2007, 13:S17-S23.
49. Colecchia A., Scaioli E., Montrone L., et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011, 54(2):300-305.
50. Chang S., Kim S.H., Lim H.K., et al. Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT. AJR Am J Roentgenol 2005, 185:400-405.
51. Chan E.S., Yeh M.M. The use of immunohistochemistry in liver tumors. Clin Liver Dis 2010, 14:687-703.
52. Di Tommaso L., Destro A., Seok J.Y., et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009, 50:746-754.
53. Wang X.Y., Degos F., Dubois S., et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006, 37:1435-1441.
54. Wang F.H., Yip Y.C., Zhang M., et al. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol 2010, 63:599-603.
55. Libbrecht L., Severi T., Cassiman D., et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006, 30:1405-1411.
56. Llovet J.M., Chen Y., Wurmbach E., et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131:1758-1767.
57. Shafizadeh N., Ferrell L.D., Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008, 21:1011-1018.